What is TidalSense, the UK healthtech startup that recently raised $19M, and how does its AI-powered N-Tidal Diagnose test aim to transform COPD diagnosis by reducing test time from an hour to under five minutes, what funding has it raised to date, how does the test work, what ar

Recent $19M Funding Round

Amount: $19 million (approximately £14.2 million / €16.6 million) .

Date announced: July 24, 2026 .

Round: Series C .

Lead investor: Cross-Border Impact Ventures .

Participating investors: Returning backers BGF, Airstream Capital, Foresight Group, and Downing .

Total funding to date: Specific cumulative figures are not publicly broken down in a single source, but the company has raised at least this Series C plus prior rounds from BGF, Airstream Capital, and Foresight Group . The device is already CE-marked and deployed in NHS regions in England prior to this raise .

Key UK COPD Statistics

• Diagnosed cases: Approximately 1.4 million people in the UK have a diagnosed COPD .
• Undiagnosed estimate: The true number is thought to be much higher; around 3.2 million adults may have COPD, with up to 2.1 million people (roughly 70%) undiagnosed .
• Prevalence: COPD affects about 2% of the total UK population and 4.5% of people over 40 . More broadly, studies estimate COPD prevalence between 3% and 6% of the population .
• Mortality: Around 30,000 people per year in the UK die from COPD , making it the second most common lung disease after asthma .
• Hospital admissions: In England in the financial year ending 2025, there were 118,975 emergency admissions for COPD (rate of 201 per 100,000 population) .

Rollout Plans

TidalSense plans to use the Series C funding for three main expansion tracks :

1. Expand across Europe – Commercialise and scale N-Tidal Diagnose in additional European markets.
2. Enter the U.S. market – Pursue regulatory clearance (FDA) and launch in the United States.
3. Scale within the NHS – Broaden deployment across more NHS regions in England beyond current early-adopter sites, and explore use in primary care to help close the diagnosis gap .

CEO Background

Dr Ameera Patel, MD PhD, is the Chief Executive Officer . She is an asthma patient herself, which gave her first-hand experience of the challenges of living with a long-term respiratory condition . Her personal difficulty in getting her own asthma diagnosed motivated her to build a better diagnostic approach. She holds both an MD and a PhD and leads the company from its Cambridge, UK headquarters .